Gilead Sciences (GILD) EPS (Weighted Average and Diluted) (QoQ) (2009 - 2026)

Gilead Sciences (GILD) EPS (Weighted Average and Diluted) (QoQ) (2009 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn
10 Novartis Ag 109.78 Bn 109.09 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 -7.47%
Dec 31, 2025 -28.40%
Sep 30, 2025 55.77%
Jun 30, 2025 50.00%
Mar 31, 2025 -26.76%
Dec 31, 2024 42.00%
Sep 30, 2024 -22.48%
Jun 30, 2024 138.62%
Mar 31, 2024 -395.58%
Dec 31, 2023 -34.68%
Sep 30, 2023 108.43%
Jun 30, 2023 3.75%
Mar 31, 2023 -38.46%
Dec 31, 2022 -8.45%
Sep 30, 2022 56.04%
Jun 30, 2022 4,450.00%
Mar 31, 2022 -93.33%
Dec 31, 2021 -85.37%
Sep 30, 2021 69.42%
Jun 30, 2021 -11.68%